Another compelling therapeutic target for CLL with ATM defect is DNA-PK (Figure 3), in light of its role in mediating NHEJ [148], the DSB-repair backup pathway of low fidelity that serves as an alternative to ATM-dependent homologous recombination [133]. Here, ATM is linked to B-cell chronic lymphocytic leukemia.